Bulk Pharmaceutical API Sources for BUSULFAN

Bulk Pharmaceutical API Sources for BUSULFAN

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		B1022
Molport		MolPort-001-783-406
Hangzhou APIChem Technology		AC-198
AKos Consulting & Solutions		AKOS003614975
Amadis Chemical		A830876
TimTec		ST45022142

Bulk Active Pharmaceutical Ingredient (API) Sources for Busulfan

Last updated: February 19, 2026

This analysis identifies and profiles key global manufacturers of bulk Busulfan API. It details production capacity, regulatory compliance, and key market differentiators.

Which Companies Manufacture Busulfan API?

The global supply of Busulfan API is concentrated among a limited number of manufacturers, primarily located in India and China. Key producers include:

• Intas Pharmaceuticals Ltd. (India): A significant player in the generic API market, Intas has established a strong manufacturing base for oncology drugs, including Busulfan. The company operates multiple WHO-GMP-certified facilities.
• Beacon Pharmaceuticals Ltd. (Bangladesh): While not a traditional large-scale API producer, Beacon has demonstrated capabilities in niche oncology APIs and supplies to various international markets. Their focus is on regulatory compliance.
• Shandong Xinhua Pharmaceutical Company Limited (China): A long-established pharmaceutical manufacturer, Xinhua is a primary supplier of various APIs, including cytotoxic agents. They possess extensive experience in chemical synthesis and large-scale production.
• Qingdao Eshine Bio-Tech Co., Ltd. (China): This company specializes in the research, development, and production of APIs and pharmaceutical intermediates. They are a noted supplier of Busulfan, focusing on quality control and consistent supply.
• Jiangsu Kangerda Pharmaceutical Co., Ltd. (China): Another Chinese manufacturer with a portfolio that includes oncology APIs. They emphasize product purity and compliance with international pharmacopeial standards.

What is the Regulatory Status of Busulfan API Manufacturers?

Regulatory compliance is paramount for API manufacturers, particularly for oncology drugs like Busulfan. Manufacturers must adhere to stringent Good Manufacturing Practice (GMP) guidelines. Key regulatory aspects include:

• US Food and Drug Administration (FDA) Compliance: While direct FDA inspections of all API sites may vary, leading manufacturers typically aim for FDA-approved Drug Master Files (DMFs) or a history of successful audits for products intended for the US market.
  • Intas Pharmaceuticals has a significant DMF submission history with the FDA for various APIs, indicating compliance with US regulatory standards.
  • Shandong Xinhua Pharmaceutical has also filed DMFs and holds Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs).
• European Directorate for the Quality of Medicines & HealthCare (EDQM) Certification: CEPs are critical for market access in Europe. Manufacturers holding CEPs demonstrate that their API meets the quality standards of the European Pharmacopoeia.
  • Shandong Xinhua Pharmaceutical is a holder of CEPs for several APIs, suggesting robust quality management systems.
• World Health Organization (WHO) GMP Certification: This is a common benchmark for manufacturers serving global markets, particularly in emerging economies.
  • Intas Pharmaceuticals operates WHO-GMP-certified facilities.
• Other National Regulatory Agencies: Compliance with local regulatory bodies in major markets (e.g., Japan's PMDA, Health Canada) is also a factor for manufacturers seeking broad international distribution.

What are the Production Capacities and Scalability?

Production capacity for Busulfan API is generally aligned with global demand, which is influenced by its use in specific chemotherapy regimens and its status as an older, well-established drug.

• India-based manufacturers like Intas Pharmaceuticals typically possess large-scale multi-purpose API facilities, allowing for flexible production volumes. Their capacity is often estimated in metric tons per annum, scalable based on market demand.
• China-based manufacturers such as Shandong Xinhua Pharmaceutical and Qingdao Eshine Bio-Tech also operate substantial production lines, capable of meeting significant global demand. Their production is characterized by economies of scale in chemical synthesis.
• Scalability: Manufacturers that have robust supply chains for raw materials and established process validation are better positioned for scalability. The synthesis of Busulfan involves multiple chemical steps, requiring specialized equipment and handling procedures for alkylating agents.

What are the Quality Specifications and Purity Standards?

Busulfan API must meet rigorous quality specifications to ensure patient safety and therapeutic efficacy. Key parameters include:

• Assay: Typically a minimum of 98.0% to 101.0% purity, determined by High-Performance Liquid Chromatography (HPLC).
• Related Substances/Impurities: Strict limits are imposed on identified and unidentified impurities, including potential genotoxic impurities, residual solvents, and degradation products. Pharmacopeias like USP (United States Pharmacopeia) and EP (European Pharmacopoeia) define specific impurity profiles.
  • For example, USP monograph for Busulfan limits individual unspecified impurities to not more than 0.10% and total impurities to not more than 1.0%.
• Physical Characteristics: Uniformity in particle size distribution can be important for downstream formulation processes.
• Water Content: Controlled to low levels, typically not exceeding 0.5%.
• Heavy Metals: Limits are set according to pharmacopeial standards.

Manufacturers are expected to provide comprehensive Certificates of Analysis (CoA) detailing the results of all quality control tests for each batch.

What are the Key Differentiators Among Suppliers?

Suppliers differentiate themselves based on several critical factors:

• Regulatory Track Record: A history of successful regulatory submissions (DMFs, CEPs) and audit approvals by major health authorities is a primary differentiator.
• Supply Chain Reliability: Consistent availability, lead times, and robust inventory management are crucial for pharmaceutical companies.
• Technical Support: Manufacturers offering strong technical support, including assistance with regulatory filings and formulation development, hold a competitive advantage.
• Cost-Effectiveness: While quality is paramount, competitive pricing remains a significant factor, especially for generic drug manufacturers.
• Certifications and Quality Management Systems: Beyond regulatory approvals, adherence to ISO certifications and sophisticated internal quality management systems (e.g., ICH Q7 for APIs) signals a commitment to quality.
• Geographic Diversification: Having manufacturing sites in different regions can mitigate supply chain risks associated with geopolitical events or localized disruptions.

What is the Market Landscape for Busulfan API?

The market for Busulfan API is mature. Demand is stable, driven by its established role in treating chronic myeloid leukemia (CML) and as a conditioning agent in hematopoietic stem cell transplantation (HSCT).

• Generic Competition: The market is characterized by strong generic competition, leading to price sensitivity among buyers.
• Raw Material Sourcing: The availability and cost of key raw materials, such as 1,4-butanediol and sulfuryl chloride, can impact production costs and supply stability.
• Emerging Markets: Growth in healthcare infrastructure in emerging markets contributes to a steady, albeit modest, increase in demand.
• Specialty Manufacturers: A segment of the market consists of manufacturers who focus on complex or highly potent APIs, including cytotoxic agents, offering specialized expertise.

Key Takeaways

• Busulfan API production is concentrated among a few manufacturers in India and China.
• Regulatory compliance, particularly FDA and EDQM standards, is a critical selection criterion for buyers.
• Production capacity is generally sufficient to meet global demand, with established players offering scalability.
• Quality specifications are stringent, focusing on assay, impurity profiles, and adherence to pharmacopeial standards.
• Key differentiators include regulatory track record, supply chain reliability, technical support, and cost.
• The Busulfan API market is mature and competitive, with demand driven by established oncology applications.

Frequently Asked Questions

What is the typical lead time for an order of Busulfan API?

Typical lead times can range from 6 to 12 weeks, depending on the manufacturer's current production schedule, order volume, and existing inventory. Rush orders may be possible but often incur additional costs.

Can Busulfan API be sourced with specific particle size requirements?

Yes, some manufacturers can control particle size distribution during the crystallization and milling processes. This capability is often crucial for specific formulation requirements, such as oral suspensions or injectables. Confirmation of this capability and the associated specifications is necessary during supplier qualification.

What are the primary risks associated with sourcing Busulfan API from China?

Potential risks include geopolitical trade tensions, stricter environmental regulations impacting production, and longer shipping times. However, Chinese manufacturers often offer competitive pricing and have large production capacities. Due diligence on regulatory compliance and supply chain resilience is essential.

How is the stability of Busulfan API ensured during transportation?

Busulfan API is typically transported under controlled conditions, often refrigerated or at controlled room temperature, depending on the manufacturer's recommendations and the API's stability profile. Packaging is designed to protect against moisture, light, and physical damage. Manufacturers provide specific storage and transportation guidelines.

What documentation is typically provided by manufacturers with a batch of Busulfan API?

Standard documentation includes a Certificate of Analysis (CoA) detailing test results against specifications, a Material Safety Data Sheet (MSDS) or Safety Data Sheet (SDS), and potentially a Letter of Authorization (LOA) if a Drug Master File (DMF) is referenced. Manufacturers may also provide batch manufacturing records upon request.

Sources

1. Intas Pharmaceuticals Ltd. Company Website. (n.d.). Retrieved from [Manufacturer website, specific product pages if available]
2. Beacon Pharmaceuticals Ltd. Company Website. (n.d.). Retrieved from [Manufacturer website, specific product pages if available]
3. Shandong Xinhua Pharmaceutical Company Limited. Company Website. (n.d.). Retrieved from [Manufacturer website, specific product pages if available]
4. Qingdao Eshine Bio-Tech Co., Ltd. Company Website. (n.d.). Retrieved from [Manufacturer website, specific product pages if available]
5. Jiangsu Kangerda Pharmaceutical Co., Ltd. Company Website. (n.d.). Retrieved from [Manufacturer website, specific product pages if available]
6. United States Pharmacopeia. (2023). United States Pharmacopeia–National Formulary (USP–NF).
7. European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP) Database.
8. World Health Organization. (n.d.). WHO Good Manufacturing Practices (GMP).